1. ALLA AKTIER
  2. NYHETER
  3. INITIATOR PHARMA

Initiator Pharma

Nyheter Initiator Pharma Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

INITIATOR PHARMA: YEAR END REPORT 2023

MARKN.

Business highlights in Q4 2023

  • In October the company announced positive results from its Phase IIb clinical trial with pudafensine (IP2015) for the treatment of erectile dysfunction (ED). The study data analysis has demonstrated statistically significant and clinically relevant efficacy in ED-related endpoints and no observations of critical adverse events. The positive results, both regarding efficacy and safety, support further development of pudafensine aiming at registration and launch in this patient group with significant unmet medical need.

Business highlights after this reporting period

  • In January the company announced that it has expanded its position to a broader Sexual Health Franchise including both male Erectile Dysfunction (ED) and Female Sexual Dysfunction (FSD) indications and intensifies its business development efforts.
  • In January the company announed the issuance of new shares and directed share buyback, as well as the sale of shares in connection with the long-term incentive program for 2021.
  • In February the company announced that MAC Clinical Research has converted its convertible loan into shares in Initiator Pharma.

Financial Highlights

Fourth Quarter (2023-10-01 – 2023-12-31)
Net revenue were TDKK 0 (0)
Operating loss, EBIT was TDKK -4,279 (-6,477)
Earnings per share before and after dilution was DKK 0.03 (-0.06)
Cash: TDKK 24,336 (39,112)
Solidity: 37% (72%)
Full Year (2023-01-01 – 2023-12-31)
Net revenues were TDKK 0 (0)
Operating loss, EBIT was TDKK -27,029 (-41,740)
Earnings per share before and after dilution was DKK –0.44 (-0.73)

Solidity: equity divided by assets.

The Board of Directors have decided that interim reports will be published in English only.

Link to the full report
https://www.initiatorpharma.com/en/investors/reports-and-presentations/

For additional information about Initiator Pharma, please contact:

Claus Elsborg Olesen, CEO
Telephone: +45 6126 0035
E-mail: ceo@initiatorpharma.com

About Initiator Pharma

Initiator Pharma A/S is a Danish clinical stage emerging pharma company developing innovative drugs that target key unmet medical needs within the central and peripheral nervous system. Initiator Pharma’s pipeline consists of two clinical stage assets – pudafensine (IP2015) and IP2018 – and two preclinical assets. The company is currently conducting a Phase IIb trial with pudafensine (IP2015) in erectile dysfunction of organic origin, and successfully completed a Phase I proof of principle trial in neuropathic pain in 2022. With IP2018 the company has reported positive, statistically significant, and dose-dependent clinical observations related to efficacy in psychogenic erectile dysfunction (ED) in a Phase IIa clinical trial of IP2018 in patients with mild to moderate ED.
 
Initiator Pharma is listed on Nasdaq First North Growth Market (ticker: INIT). Redeye AB is the company’s Certified Adviser. For more information, please visit www.initiatorpharma.com.

Attachments

Q4 2023 Initiator Final

Datum 2024-02-23, kl 08:30
Källa MFN
Bifogade filer
Q4 2023 Initiator Final